These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

417 related articles for article (PubMed ID: 14507946)

  • 21. Safety and efficacy of trastuzumab every 3 weeks combined with cytotoxic chemotherapy in patients with HER2-positive recurrent breast cancer: findings from a case series.
    Ardavanis A; Tryfonopoulos D; Orfanos G; Karamouzis M; Scorilas A; Alexopoulos A; Rigatos G
    Onkologie; 2005 Nov; 28(11):558-64. PubMed ID: 16249641
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A pilot study of adjuvant nanoparticle albumin-bound (nab) paclitaxel and cyclophosphamide, with trastuzumab in HER2-positive patients, in the treatment of early-stage breast cancer.
    Yardley D; Burris H; Peacock N; Raefsky E; Melnik M; Inhorn R; Shipley D; Hainsworth J
    Breast Cancer Res Treat; 2010 Sep; 123(2):471-5. PubMed ID: 20658263
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.
    Marty M; Cognetti F; Maraninchi D; Snyder R; Mauriac L; Tubiana-Hulin M; Chan S; Grimes D; Antón A; Lluch A; Kennedy J; O'Byrne K; Conte P; Green M; Ward C; Mayne K; Extra JM
    J Clin Oncol; 2005 Jul; 23(19):4265-74. PubMed ID: 15911866
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety and activity of docetaxel and trastuzumab in HER2 overexpressing metastatic breast cancer: a pilot phase II study.
    Montemurro F; Choa G; Faggiuolo R; Sperti E; Capaldi A; Donadio M; Minischetti M; Salomone A; Vietti-Ramus G; Alabiso O; Aglietta M
    Am J Clin Oncol; 2003 Feb; 26(1):95-7. PubMed ID: 12576933
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer.
    Krop IE; Beeram M; Modi S; Jones SF; Holden SN; Yu W; Girish S; Tibbitts J; Yi JH; Sliwkowski MX; Jacobson F; Lutzker SG; Burris HA
    J Clin Oncol; 2010 Jun; 28(16):2698-704. PubMed ID: 20421541
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Trastuzumab plus weekly epirubicin and paclitaxel for locally advanced and metastatic breast cancer: preliminary results of a feasibility-phase II study aimed at cardiotoxicity.
    Nisticò C; Bria E; Vaccaro V; Cuppone F; Fornier M; Sperduti I; Carpino A; Izzo F; Tropea F; Cognetti F; Terzoli E
    Anticancer Drugs; 2009 Feb; 20(2):109-14. PubMed ID: 19209027
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Response and cardiac toxicity of trastuzumab given in conjunction with weekly paclitaxel after doxorubicin/cyclophosphamide.
    Kelly H; Kimmick G; Dees EC; Collichio F; Gatti L; Sawyer L; Ivanova A; Dressler L; Graham ML; Carey LA
    Clin Breast Cancer; 2006 Aug; 7(3):237-43. PubMed ID: 16942640
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm.
    Burstein HJ; Harris LN; Marcom PK; Lambert-Falls R; Havlin K; Overmoyer B; Friedlander RJ; Gargiulo J; Strenger R; Vogel CL; Ryan PD; Ellis MJ; Nunes RA; Bunnell CA; Campos SM; Hallor M; Gelman R; Winer EP
    J Clin Oncol; 2003 Aug; 21(15):2889-95. PubMed ID: 12885806
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840.
    Seidman AD; Berry D; Cirrincione C; Harris L; Muss H; Marcom PK; Gipson G; Burstein H; Lake D; Shapiro CL; Ungaro P; Norton L; Winer E; Hudis C
    J Clin Oncol; 2008 Apr; 26(10):1642-9. PubMed ID: 18375893
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Feasibility and cardiac safety of pegylated liposomal doxorubicin plus trastuzumab in heavily pretreated patients with recurrent HER2-overexpressing metastatic breast cancer.
    Andreopoulou E; Gaiotti D; Kim E; Volm M; Oratz R; Freedberg R; Downey A; Vogel CL; Chia S; Muggia F
    Clin Breast Cancer; 2007 Aug; 7(9):690-6. PubMed ID: 17919349
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.
    Klaassen U; Wilke H; Seeber S
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):32-7. PubMed ID: 8893897
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neoadjuvant weekly paclitaxel with and without trastuzumab in locally advanced or metastatic breast cancer.
    Horiguchi J; Oyama T; Koibuchi Y; Yokoe T; Takata D; Ikeda F; Nagaoka H; Rokutanda N; Nagaoka R; Ishikawa Y; Odawara H; Kikuchi M; Sato A; Iino Y; Takeyoshi I
    Anticancer Res; 2009 Feb; 29(2):517-24. PubMed ID: 19331197
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy.
    Burris HA; Rugo HS; Vukelja SJ; Vogel CL; Borson RA; Limentani S; Tan-Chiu E; Krop IE; Michaelson RA; Girish S; Amler L; Zheng M; Chu YW; Klencke B; O'Shaughnessy JA
    J Clin Oncol; 2011 Feb; 29(4):398-405. PubMed ID: 21172893
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A phase II study of three-weekly docetaxel and weekly trastuzumab in HER2-overexpressing advanced breast cancer.
    Montemurro F; Choa G; Faggiuolo R; Donadio M; Minischetti M; Durando A; Capaldi A; Vietti-Ramus G; Alabiso O; Aglietta M
    Oncology; 2004; 66(1):38-45. PubMed ID: 15031597
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer.
    Buzdar AU; Ibrahim NK; Francis D; Booser DJ; Thomas ES; Theriault RL; Pusztai L; Green MC; Arun BK; Giordano SH; Cristofanilli M; Frye DK; Smith TL; Hunt KK; Singletary SE; Sahin AA; Ewer MS; Buchholz TA; Berry D; Hortobagyi GN
    J Clin Oncol; 2005 Jun; 23(16):3676-85. PubMed ID: 15738535
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pathological complete response and prognosis in patients receiving neoadjuvant paclitaxel and trastuzumab with and without anthracyclines for stage II and III, HER2-positive operable breast cancer: a single-institute experience.
    Horiguchi J; Oyama T; Takata D; Rokutanda N; Nagaoka R; Odawara H; Tokiniwa H; Tozuka K; Kikuchi M; Sato A; Takeyoshi I
    Anticancer Res; 2011 Sep; 31(9):3041-6. PubMed ID: 21868556
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Trastuzumab retreatment after relapse on adjuvant trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer: final results of the Retreatment after HErceptin Adjuvant trial.
    Láng I; Bell R; Feng FY; Lopez RI; Jassem J; Semiglazov V; Al-Sakaff N; Heinzmann D; Chang J
    Clin Oncol (R Coll Radiol); 2014 Feb; 26(2):81-9. PubMed ID: 24051172
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A phase I study of cetuximab/paclitaxel in patients with advanced-stage breast cancer.
    Modi S; D'Andrea G; Norton L; Yao TJ; Caravelli J; Rosen PP; Hudis C; Seidman AD
    Clin Breast Cancer; 2006 Aug; 7(3):270-7. PubMed ID: 16942645
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Multicenter, phase II, nonrandomized study of docetaxel plus trastuzumab every 21 days as the primary therapy in metastatic breast cancer overexpressing HER2.
    Servitja S; Ramos M; Gil M; Sánchez-Rovira P; Vázquez-Estevez S; Virizuela JA; García-Estevez L; Velasco A; Tusquets I
    Anticancer Drugs; 2012 Feb; 23(2):239-46. PubMed ID: 22112931
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pegylated liposomal doxorubicin and trastuzumab as 1st and 2nd line therapy in her2/neu positive metastatic breast cancer: a multicenter phase II trial.
    Stickeler E; Klar M; Watermann D; Geibel A; Földi M; Hasenburg A; Gitsch G
    Breast Cancer Res Treat; 2009 Oct; 117(3):591-8. PubMed ID: 19156515
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.